Literature DB >> 2532060

Hairy cell sensitivity to the lysis in vitro. Role of the anti-CD3 antibody in generating a susceptibility to the lysis.

G Semenzato1, L Trentin, R Zambello, C Agostini, T Chisesi, G Pizzolo.   

Abstract

Experiments herein reported were designed to clarify the degree of sensitivity of hairy cells to lysis in vitro. The cytotoxic capacity of peripheral blood lymphocytes from hairy cell leukemia patients against autologous and/or allogenic hairy cells was tested both at resting conditions and after in vitro stimulation. While effectors activated by interferon alpha, lectins, or interleukin-2 were unable to induce a lysis of hairy cells, in some cases we were successful in eliciting a definite lysis of these cells by triggering the effector cells with anti-CD3 monoclonal antibodies. Our results favour the interpretation that hairy cells are relatively, but not completely resistant to in vitro lysis. Furthermore, the evidence that anti-CD3 antibodies increase the efficacy of the cytotoxic machinery might support the use of these molecules in designing new immunotherapeutic approaches against tumor targets.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532060     DOI: 10.1007/bf01665013

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  Hairy cells are not lysed by autologous LAK cells.

Authors:  J Demeter; M Benczur
Journal:  Blut       Date:  1989-01

2.  Alpha-interferon activates the natural killer system in patients with hairy cell leukemia.

Authors:  G Semenzato; G Pizzolo; C Agostini; A Ambrosetti; R Zambello; L Trentin; M Luca; M Masciarelli; M Chilosi; F Vinante
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

Review 3.  Clinical trials in hairy cell leukemia. Current status and future directions.

Authors:  B D Cheson; A Martin
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

4.  Hairy-cells are not lysed by NK-cells.

Authors:  F Sigaux; F Chapuis; S Castaigne; L Degos; G Flandrin; J C Gluckman
Journal:  Blut       Date:  1987-05

5.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events.

Authors:  L Trentin; A Ambrosetti; R Zambello; C Agostini; M Masciarelli; F Vinante; M Chilosi; G Pizzolo; G Cetto; G Semenzato
Journal:  Leuk Res       Date:  1987       Impact factor: 3.156

7.  Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

Authors:  E Lotzová; C A Savary; R B Herberman
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

8.  Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results.

Authors:  K A Foon; A E Maluish; P G Abrams; S Wrightington; H C Stevenson; A Alarif; M F Fer; W R Overton; M Poole; E F Schnipper
Journal:  Am J Med       Date:  1986-03       Impact factor: 4.965

9.  Synergistic interaction between anti-CD3 and IL-2 demonstrated by proliferative response, interferon production, and non-MHC-restricted killing.

Authors:  Z Tovar; M Dauphinée; N Talal
Journal:  Cell Immunol       Date:  1988-11       Impact factor: 4.868

10.  Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody.

Authors:  S S Sung; J M Bjorndahl; C Y Wang; H T Kao; S M Fu
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.